We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+15.25%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$126M
AUM Growth
+$10.2M
Cap. Flow
-$1.82M
Cap. Flow %
-1.44%
Top 10 Hldgs %
41.21%
Holding
109
New
16
Increased
15
Reduced
24
Closed
15

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$2.72M
2
SYRE icon
Spyre Therapeutics
SYRE
+$2.69M
3
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$2.28M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$2.22M
5
LOXO
Loxo Oncology, Inc
LOXO
+$1.57M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$2.45M
2
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$2.19M
3
BEAT
BioTelemetry, Inc.
BEAT
+$2M
4
MASI
Masimo
MASI
+$1.7M
5
CYAD
Celyad Oncology SA American Depositary Shares
CYAD
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 71.02%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCYX icon
51
SCYNEXIS
SCYX
$36M
$579K 0.46%
3,336
+1,375
+70% +$389K
INNL
52
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$551K 0.44%
+100,000
New +$819K
INDP icon
53
Indaptus Therapeutics
INDP
$231M
$549K 0.44%
53
– –
MASI
54
DELISTED
Masimo
MASI
$525K 0.42%
10,000
-36,010
-78% -$1.7M
BLUE
55
DELISTED
bluebird bio
BLUE
$519K 0.41%
926
– –
TTPH
56
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$446K 0.35%
+5,185
New +$475K
ADVM
57
DELISTED
Adverum Biotechnologies
ADVM
$444K 0.35%
14,060
– –
ABEO icon
58
Abeona Therapeutics
ABEO
$343M
$429K 0.34%
7,273
– –
VTVT icon
59
vTv Therapeutics
VTVT
$122M
$423K 0.34%
1,825
– –
NEOS
60
DELISTED
Neos Therapeutics, Inc
NEOS
$361K 0.29%
38,873
– –
PVLA
61
Palvella Therapeutics
PVLA
$2.05B
$360K 0.29%
2,792
+2,164
+345% +$332K
DRNA
62
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$358K 0.28%
119,300
-1,300
-1% -$5.34K
CGNT
63
DELISTED
Cogentix Medical, Inc.
CGNT
$339K 0.27%
352,882
– –
ARDX icon
64
Ardelyx
ARDX
$1.25B
$262K 0.21%
30,000
-110,265
-79% -$901K
ABUS icon
65
Arbutus Biopharma
ABUS
$871M
$261K 0.21%
75,000
-40,230
-35% -$170K
DXTR
66
DELISTED
Dextera Surgical Inc.
DXTR
$252K 0.2%
+140,275
New +$287K
AVEO
67
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$249K 0.2%
+25,907
New +$250K
NDRM
68
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$234K 0.19%
14,421
+13,219
+1,100% +$223K
VIRX
69
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$232K 0.18%
2,016
– –
BPMC
70
DELISTED
Blueprint Medicines
BPMC
$205K 0.16%
+10,100
New +$184K
CBIO
71
Crescent Biopharma
CBIO
$608M
$204K 0.16%
+280
New +$193K
TENX icon
72
Tenax Therapeutics
TENX
$419M
$204K 0.16%
2
– –
ADAP
73
DELISTED
Adaptimmune Therapeutics
ADAP
$203K 0.16%
24,955
-63,145
-72% -$595K
AKBA icon
74
Akebia Therapeutics
AKBA
$341M
$185K 0.15%
24,700
-41,000
-62% -$358K
VTGN icon
75
VistaGen Therapeutics
VTGN
$9.55M
$183K 0.15%
+1,563
New +$179K
1 2
3
4 5

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, DAFNA Capital Management held 109 positions worth $126M, up 8.8% from $116M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

DAFNA Capital Management's Q2 2016 filing shows 16 new, 15 increased, 24 reduced and 15 closed positions. Its largest new stake was Immunomedics Inc: 815,000 shares worth $1.89M. The largest sale was AbbVie, an estimated $2.45M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 73% a quarter earlier, followed by Financials.

  • DAFNA Capital Management's largest Q2 2016 buy was Immunomedics Inc: 815,000 shares worth $1.89M.
  • DAFNA Capital Management added most to CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q2 2016, an estimated $2.28M increase.
  • DAFNA Capital Management's biggest Q2 2016 reduction was AbbVie, cutting an estimated $2.45M.
  • DAFNA Capital Management fully exited Celyad Oncology SA American Depositary Shares in Q2 2016, selling an estimated $1.32M.
  • DAFNA Capital Management's ten largest holdings make up 41% of its $126M portfolio in Q2 2016.
  • DAFNA Capital Management opened 16 new positions and closed 15 in Q2 2016.
  • DAFNA Capital Management's portfolio value rose 8.8% quarter-over-quarter to $126M.

Based on DAFNA Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.